Clinical Trials Logo

Malignant Paraganglioma clinical trials

View clinical trials related to Malignant Paraganglioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04860700 Completed - Clinical trials for Malignant Paraganglioma

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma. Anlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT03008369 Completed - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Start date: May 31, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02592356 Completed - Clinical trials for Thyroid Gland Medullary Carcinoma

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Start date: November 16, 2015
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

NCT ID: NCT01155258 Completed - Clinical trials for Stage IV Breast Cancer

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.